The biotech firm’s cash reserves surged to $377.7 million as of June 30, 2026, nearly doubling from year-end 2025.
Solid Biosciences reported a Q2 GAAP loss of $0.38 per share, narrower than the expected $0.08 miss. The smaller deficit reflects improved cost management amid ongoing clinical development efforts.
Cash reserves climbed to $377.7 million as of June 30, 2026, up from $187.9 million at December 31, 2025. The company attributed the increase to strategic financing activities, extending its operational runway.
The firm expects existing cash and equivalents to support operations beyond current projections, though no specific timeline was provided.